866-997-4948(US-Canada Toll Free)

Non-Small Cell Lung Cancer - Pipeline Review, H1 2016

Published By :

Global Markets Direct

Published Date : Jun 2016

Category :

Cancer

No. of Pages : 2025 Pages

Non-Small Cell Lung Cancer - Pipeline Review, H1 2016

Summary

Global Markets Directs, Non-Small Cell Lung Cancer - Pipeline Review, H1 2016, provides an overview of the Non-Small Cell Lung Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Non-Small Cell Lung Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Non-Small Cell Lung Cancer and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Non-Small Cell Lung Cancer
- The report reviews pipeline therapeutics for Non-Small Cell Lung Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Non-Small Cell Lung Cancer therapeutics and enlists all their major and minor projects
- The report assesses Non-Small Cell Lung Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Non-Small Cell Lung Cancer

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Non-Small Cell Lung Cancer
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Non-Small Cell Lung Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
Introduction 13
Non-Small Cell Lung Cancer Overview 14
Therapeutics Development 15
Non-Small Cell Lung Cancer - Therapeutics under Development by Companies 17
Non-Small Cell Lung Cancer - Therapeutics under Investigation by Universities/Institutes 40
Non-Small Cell Lung Cancer - Pipeline Products Glance 43
Non-Small Cell Lung Cancer - Products under Development by Companies 47
Non-Small Cell Lung Cancer - Products under Investigation by Universities/Institutes 85
Non-Small Cell Lung Cancer - Companies Involved in Therapeutics Development 89
Non-Small Cell Lung Cancer - Therapeutics Assessment 357
Drug Profiles 431
Non-Small Cell Lung Cancer - Dormant Projects 1910
Non-Small Cell Lung Cancer - Discontinued Products 1941
Non-Small Cell Lung Cancer - Product Development Milestones 1953
Appendix 1965

List of Tables
Number of Products under Development for Non-Small Cell Lung Cancer, H1 2016 74
Number of Products under Development for Non-Small Cell Lung Cancer - Comparative Analysis, H1 2016 75
Number of Products under Development by Companies, H1 2016 77
Number of Products under Development by Companies, H1 2016 (Contd..1) 78
Number of Products under Development by Companies, H1 2016 (Contd..2) 79
Number of Products under Development by Companies, H1 2016 (Contd..3) 80
Number of Products under Development by Companies, H1 2016 (Contd..4) 81
Number of Products under Development by Companies, H1 2016 (Contd..5) 82
Number of Products under Development by Companies, H1 2016 (Contd..6) 83
Number of Products under Development by Companies, H1 2016 (Contd..7) 84
Number of Products under Development by Companies, H1 2016 (Contd..8) 85
Number of Products under Development by Companies, H1 2016 (Contd..9) 86
Number of Products under Development by Companies, H1 2016 (Contd..10) 87
Number of Products under Development by Companies, H1 2016 (Contd..11) 88
Number of Products under Development by Companies, H1 2016 (Contd..12) 89
Number of Products under Development by Companies, H1 2016 (Contd..13) 90
Number of Products under Development by Companies, H1 2016 (Contd..14) 91
Number of Products under Development by Companies, H1 2016 (Contd..15) 92
Number of Products under Development by Companies, H1 2016 (Contd..16) 93
Number of Products under Development by Companies, H1 2016 (Contd..17) 94
Number of Products under Development by Companies, H1 2016 (Contd..18) 95
Number of Products under Development by Companies, H1 2016 (Contd..19) 96
Number of Products under Development by Companies, H1 2016 (Contd..20) 97
Number of Products under Development by Companies, H1 2016 (Contd..21) 98
Number of Products under Investigation by Universities/Institutes, H1 2016 99
Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..1) 100
Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..2) 101
Comparative Analysis by Late Stage Development, H1 2016 102
Comparative Analysis by Clinical Stage Development, H1 2016 103
Comparative Analysis by Early Stage Development, H1 2016 104
Comparative Analysis by Unknown Stage Development, H1 2016 105
Products under Development by Companies, H1 2016 106
Products under Development by Companies, H1 2016 (Contd..1) 107
Products under Development by Companies, H1 2016 (Contd..2) 108
Products under Development by Companies, H1 2016 (Contd..3) 109
Products under Development by Companies, H1 2016 (Contd..4) 110
Products under Development by Companies, H1 2016 (Contd..5) 111
Products under Development by Companies, H1 2016 (Contd..6) 112
Products under Development by Companies, H1 2016 (Contd..7) 113
Products under Development by Companies, H1 2016 (Contd..8) 114
Products under Development by Companies, H1 2016 (Contd..9) 115
Products under Development by Companies, H1 2016 (Contd..10) 116
Products under Development by Companies, H1 2016 (Contd..11) 117
Products under Development by Companies, H1 2016 (Contd..12) 118
Products under Development by Companies, H1 2016 (Contd..13) 119
Products under Development by Companies, H1 2016 (Contd..14) 120
Products under Development by Companies, H1 2016 (Contd..15) 121
Products under Development by Companies, H1 2016 (Contd..16) 122
Products under Development by Companies, H1 2016 (Contd..17) 123
Products under Development by Companies, H1 2016 (Contd..18) 124
Products under Development by Companies, H1 2016 (Contd..19) 125
Products under Development by Companies, H1 2016 (Contd..20) 126
Products under Development by Companies, H1 2016 (Contd..21) 127
Products under Development by Companies, H1 2016 (Contd..22) 128
Products under Development by Companies, H1 2016 (Contd..23) 129
Products under Development by Companies, H1 2016 (Contd..24) 130
Products under Development by Companies, H1 2016 (Contd..25) 131
Products under Development by Companies, H1 2016 (Contd..26) 132
Products under Development by Companies, H1 2016 (Contd..27) 133
Products under Development by Companies, H1 2016 (Contd..28) 134
Products under Development by Companies, H1 2016 (Contd..29) 135
Products under Development by Companies, H1 2016 (Contd..30) 136
Products under Development by Companies, H1 2016 (Contd..31) 137
Products under Development by Companies, H1 2016 (Contd..32) 138
Products under Development by Companies, H1 2016 (Contd..33) 139
Products under Development by Companies, H1 2016 (Contd..34) 140
Products under Development by Companies, H1 2016 (Contd..35) 141
Products under Development by Companies, H1 2016 (Contd..36) 142
Products under Development by Companies, H1 2016 (Contd..37) 143
Products under Investigation by Universities/Institutes, H1 2016 144
Products under Investigation by Universities/Institutes, H1 2016 (Contd..1) 145
Products under Investigation by Universities/Institutes, H1 2016 (Contd..2) 146
Products under Investigation by Universities/Institutes, H1 2016 (Contd..3) 147
Non-Small Cell Lung Cancer - Pipeline by 3-V Biosciences, Inc., H1 2016 148
Non-Small Cell Lung Cancer - Pipeline by 4SC AG, H1 2016 149
Non-Small Cell Lung Cancer - Pipeline by AbbVie Inc., H1 2016 150
Non-Small Cell Lung Cancer - Pipeline by Ability Pharmaceuticals, S.L., H1 2016 151
Non-Small Cell Lung Cancer - Pipeline by ACEA Biosciences, Inc., H1 2016 152
Non-Small Cell Lung Cancer - Pipeline by Acetylon Pharmaceuticals, Inc., H1 2016 153
Non-Small Cell Lung Cancer - Pipeline by Adaptimmune Therapeutics Plc, H1 2016 154
Non-Small Cell Lung Cancer - Pipeline by Advanced Cancer Therapeutics, H1 2016 155
Non-Small Cell Lung Cancer - Pipeline by Advenchen Laboratories, LLC, H1 2016 156
Non-Small Cell Lung Cancer - Pipeline by Aeolus Pharmaceuticals, Inc., H1 2016 157
Non-Small Cell Lung Cancer - Pipeline by Altimmune, Inc., H1 2016 158
Non-Small Cell Lung Cancer - Pipeline by Altor BioScience Corporation, H1 2016 159
Non-Small Cell Lung Cancer - Pipeline by Amgen Inc., H1 2016 160
Non-Small Cell Lung Cancer - Pipeline by Andarix Pharmaceuticals, Inc., H1 2016 161
Non-Small Cell Lung Cancer - Pipeline by AndroScience Corporation, H1 2016 162
Non-Small Cell Lung Cancer - Pipeline by Apac Biotech Pvt Ltd, H1 2016 163
Non-Small Cell Lung Cancer - Pipeline by APO-T B.V., H1 2016 164
Non-Small Cell Lung Cancer - Pipeline by Aptose Biosciences Inc., H1 2016 165
Non-Small Cell Lung Cancer - Pipeline by Argos Therapeutics, Inc., H1 2016 166
Non-Small Cell Lung Cancer - Pipeline by Ariad Pharmaceuticals, Inc., H1 2016 167
Non-Small Cell Lung Cancer - Pipeline by Arog Pharmaceuticals, Inc., H1 2016 168
Non-Small Cell Lung Cancer - Pipeline by ArQule, Inc., H1 2016 169
Non-Small Cell Lung Cancer - Pipeline by Array BioPharma Inc., H1 2016 170
Non-Small Cell Lung Cancer - Pipeline by Arrien Pharmaceuticals, LLC, H1 2016 171
Non-Small Cell Lung Cancer - Pipeline by Astellas Pharma Inc., H1 2016 172
Non-Small Cell Lung Cancer - Pipeline by Asterias Biotherapeutics, Inc., H1 2016 173
Non-Small Cell Lung Cancer - Pipeline by Astex Pharmaceuticals, Inc., H1 2016 174
Non-Small Cell Lung Cancer - Pipeline by AstraZeneca Plc, H1 2016 175
Non-Small Cell Lung Cancer - Pipeline by ATLAB Pharma SAS, H1 2016 176
Non-Small Cell Lung Cancer - Pipeline by Aurigene Discovery Technologies Limited, H1 2016 177
Non-Small Cell Lung Cancer - Pipeline by AVEO Pharmaceuticals, Inc., H1 2016 178
Non-Small Cell Lung Cancer - Pipeline by Azaya Therapeutics, Inc., H1 2016 179
Non-Small Cell Lung Cancer - Pipeline by Basilea Pharmaceutica AG, H1 2016 180
Non-Small Cell Lung Cancer - Pipeline by Batu Biologics, Inc., H1 2016 181
Non-Small Cell Lung Cancer - Pipeline by Bavarian Nordic A/S, H1 2016 182
Non-Small Cell Lung Cancer - Pipeline by Bayer AG, H1 2016 183
Non-Small Cell Lung Cancer - Pipeline by BeiGene, Ltd., H1 2016 184
Non-Small Cell Lung Cancer - Pipeline by Benitec Biopharma Limited, H1 2016 185
Non-Small Cell Lung Cancer - Pipeline by BerGenBio AS, H1 2016 186
Non-Small Cell Lung Cancer - Pipeline by Beta Pharma, Inc., H1 2016 187
Non-Small Cell Lung Cancer - Pipeline by Betta Pharmaceuticals Co. Ltd., H1 2016 188
Non-Small Cell Lung Cancer - Pipeline by BIND Therapeutics, Inc., H1 2016 189
Non-Small Cell Lung Cancer - Pipeline by Bio-Path Holdings, Inc., H1 2016 190
Non-Small Cell Lung Cancer - Pipeline by BIOCAD, H1 2016 191
Non-Small Cell Lung Cancer - Pipeline by BioCancell Ltd, H1 2016 192
Non-Small Cell Lung Cancer - Pipeline by BioLineRx, Ltd., H1 2016 193
Non-Small Cell Lung Cancer - Pipeline by Bionovis SA, H1 2016 194
Non-Small Cell Lung Cancer - Pipeline by Blueprint Medicines Corporation, H1 2016 195
Non-Small Cell Lung Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2016 196
Non-Small Cell Lung Cancer - Pipeline by Boston Biomedical, Inc., H1 2016 197
Non-Small Cell Lung Cancer - Pipeline by Bristol-Myers Squibb Company, H1 2016 198
Non-Small Cell Lung Cancer - Pipeline by Calithera Biosciences, Inc., H1 2016 199
Non-Small Cell Lung Cancer - Pipeline by CanBas Co., Ltd., H1 2016 200
Non-Small Cell Lung Cancer - Pipeline by Cantargia AB, H1 2016 201
Non-Small Cell Lung Cancer - Pipeline by Cantex Pharmaceuticals, Inc., H1 2016 202
Non-Small Cell Lung Cancer - Pipeline by CASI Pharmaceuticals Inc., H1 2016 203
Non-Small Cell Lung Cancer - Pipeline by Celgene Corporation, H1 2016 204
Non-Small Cell Lung Cancer - Pipeline by CellAct Pharma GmbH, H1 2016 205
Non-Small Cell Lung Cancer - Pipeline by Cellceutix Corporation, H1 2016 206
Non-Small Cell Lung Cancer - Pipeline by Celldex Therapeutics, Inc., H1 2016 207
Non-Small Cell Lung Cancer - Pipeline by Cellectar Biosciences, Inc., H1 2016 208
Non-Small Cell Lung Cancer - Pipeline by Cellectis S.A., H1 2016 209
Non-Small Cell Lung Cancer - Pipeline by Cellmid Limited, H1 2016 210
Non-Small Cell Lung Cancer - Pipeline by Celltrion, Inc., H1 2016 211
Non-Small Cell Lung Cancer - Pipeline by Cellular Biomedicine Group, Inc., H1 2016 212
Non-Small Cell Lung Cancer - Pipeline by Chipscreen Biosciences Ltd, H1 2016 213
Non-Small Cell Lung Cancer - Pipeline by Chugai Pharmaceutical Co., Ltd., H1 2016 214
Non-Small Cell Lung Cancer - Pipeline by Cipla Ltd., H1 2016 215
Non-Small Cell Lung Cancer - Pipeline by Clonz Biotech Private Limited, H1 2016 216
Non-Small Cell Lung Cancer - Pipeline by Coherus BioSciences, Inc., H1 2016 217
Non-Small Cell Lung Cancer - Pipeline by Corcept Therapeutics Incorporated, H1 2016 218
Non-Small Cell Lung Cancer - Pipeline by Cornerstone Pharmaceuticals, Inc., H1 2016 219
Non-Small Cell Lung Cancer - Pipeline by Corvus Pharmaceuticals, Inc., H1 2016 220
Non-Small Cell Lung Cancer - Pipeline by Critical Outcome Technologies Inc., H1 2016 221
Non-Small Cell Lung Cancer - Pipeline by CTI BioPharma Corp., H1 2016 222
Non-Small Cell Lung Cancer - Pipeline by CureVac GmbH, H1 2016 223
Non-Small Cell Lung Cancer - Pipeline by CytRx Corporation, H1 2016 224
Non-Small Cell Lung Cancer - Pipeline by Daiichi Sankyo Company, Limited, H1 2016 225
Non-Small Cell Lung Cancer - Pipeline by DanDrit Biotech A/S, H1 2016 226
Non-Small Cell Lung Cancer - Pipeline by Debiopharm International SA , H1 2016 227
Non-Small Cell Lung Cancer - Pipeline by DEKK-TEC, Inc., H1 2016 228
Non-Small Cell Lung Cancer - Pipeline by DelMar Pharmaceuticals, Inc., H1 2016 229
Non-Small Cell Lung Cancer - Pipeline by Denovo Biopharma, LLC, H1 2016 230
Non-Small Cell Lung Cancer - Pipeline by DiNonA Inc., H1 2016 231
Non-Small Cell Lung Cancer - Pipeline by Domainex Limited, H1 2016 232
Non-Small Cell Lung Cancer - Pipeline by DormaTarg, Inc., H1 2016 233
Non-Small Cell Lung Cancer - Pipeline by Double Bond Pharmaceutical International AB, H1 2016 234
Non-Small Cell Lung Cancer - Pipeline by Dr. Reddy's Laboratories Limited, H1 2016 235
Non-Small Cell Lung Cancer - Pipeline by Eagle Pharmaceuticals, Inc., H1 2016 236
Non-Small Cell Lung Cancer - Pipeline by EirGenix Inc., H1 2016 237
Non-Small Cell Lung Cancer - Pipeline by Eisai Co., Ltd., H1 2016 238
Non-Small Cell Lung Cancer - Pipeline by Eleison Pharmaceuticals LLC, H1 2016 239
Non-Small Cell Lung Cancer - Pipeline by Eli Lilly and Company, H1 2016 240
Non-Small Cell Lung Cancer - Pipeline by Endocyte, Inc., H1 2016 241
Non-Small Cell Lung Cancer - Pipeline by EnGeneIC Ltd, H1 2016 242
Non-Small Cell Lung Cancer - Pipeline by EntreChem, S.L., H1 2016 243
Non-Small Cell Lung Cancer - Pipeline by Enumeral Biomedical Holdings, Inc., H1 2016 244
Non-Small Cell Lung Cancer - Pipeline by Eudendron S.r.l., H1 2016 245
Non-Small Cell Lung Cancer - Pipeline by Exelixis, Inc., H1 2016 246
Non-Small Cell Lung Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 247


List of Figures
Number of Products under Development for Non-Small Cell Lung Cancer, H1 2016 74
Number of Products under Development for Non-Small Cell Lung Cancer - Comparative Analysis, H1 2016 75
Number of Products under Development by Companies, H1 2016 76
Number of Products under Investigation by Universities/Institutes, H1 2016 99
Comparative Analysis by Late Stage Development, H1 2016 102
Comparative Analysis by Clinical Stage Development, H1 2016 103
Comparative Analysis by Early Stage Products, H1 2016 104
Assessment by Monotherapy Products, H1 2016 416
Assessment by Combination Products, H1 2016 417
Number of Products by Top 10 Targets, H1 2016 418
Number of Products by Stage and Top 10 Targets, H1 2016 418
Number of Products by Top 10 Mechanism of Actions, H1 2016 445
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 445
Number of Products by Top 10 Routes of Administration, H1 2016 486
Number of Products by Stage and Top 10 Routes of Administration, H1 2016 486
Number of Products by Top 10 Molecule Types, H1 2016 488
Number of Products by Stage and Top 10 Molecule Types, H1 2016 488

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *